---
title: "LL-37"
slug: "ll-37"
type: "compound"
category: "Recovery"
url: "https://peptidesciencethailand.com/compounds/ll-37"
description: "The only human cathelicidin, a host defense peptide with antimicrobial and wound-healing properties. Innate immunity research and mechanism overview."
---
# LL-37

*Human Cathelicidin Antimicrobial Peptide, Bridging Innate Defense and Tissue Regeneration*

**Category:** Recovery  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >98% (HPLC)

## Overview

LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from the C-terminal cleavage of the 18 kDa precursor protein hCAP18 (human cationic antimicrobial protein 18). The peptide derives its name from its two N-terminal leucine (L) residues and its 37-amino acid length. LL-37 is produced by a wide range of cell types including neutrophils, macrophages, epithelial cells, keratinocytes, and mast cells, and is encoded by the CAMP (cathelicidin antimicrobial peptide) gene located on chromosome 3. Its expression is regulated by multiple factors including vitamin D receptor signaling, inflammatory cytokines, and microbial pattern recognition, positioning it as a key effector molecule at the intersection of innate immunity and tissue homeostasis.

Structurally, LL-37 adopts an amphipathic alpha-helical conformation in physiological environments, with hydrophobic residues aligned along one face and cationic residues along the opposite face. This amphipathic architecture is critical for its membrane-disrupting antimicrobial activity. The peptide carries a net positive charge of +6 at physiological pH, enabling electrostatic interaction with negatively charged microbial membrane components including lipopolysaccharide (LPS) in Gram-negative bacteria, lipoteichoic acid (LTA) in Gram-positive bacteria, and phospholipids in fungal and viral membranes.

The antimicrobial mechanism of LL-37 involves multiple complementary membrane-disrupting strategies. The carpet model describes LL-37 molecules accumulating parallel to the microbial membrane surface until a critical concentration is reached, at which point they collectively disrupt membrane integrity. The toroidal pore model involves LL-37 molecules inserting into the membrane and forming transmembrane pores that dissipate the electrochemical gradient essential for microbial viability. Additionally, LL-37 can translocate across microbial membranes and interfere with intracellular processes including DNA and RNA synthesis, protein folding, and cell wall biosynthesis. This multi-target antimicrobial mechanism makes development of microbial resistance to LL-37 inherently difficult.

Beyond direct antimicrobial activity, LL-37 functions as a potent immunomodulatory molecule with diverse effects on both innate and adaptive immune cells. The peptide activates formyl peptide receptor 2 (FPR2/ALX), a G-protein-coupled receptor expressed on neutrophils, monocytes, and macrophages. FPR2 engagement triggers chemotaxis, bringing immune cells to sites of infection or tissue damage. LL-37 also activates the P2X7 purinergic receptor on macrophages, inducing inflammasome assembly and IL-1beta processing, a critical inflammatory pathway for intracellular pathogen clearance.

LL-37's wound healing properties have been extensively characterized and extend well beyond its antimicrobial function. The peptide promotes keratinocyte migration through transactivation of the epidermal growth factor receptor (EGFR), initiating downstream signaling through the MAPK/ERK pathway that drives cell proliferation and migration essential for re-epithelialization. Additionally, LL-37 stimulates angiogenesis in wound tissue by directly activating FPR2 on endothelial cells and by inducing VEGF expression through HIF-1alpha stabilization, ensuring adequate blood supply to healing tissue.

The peptide also modulates the inflammatory microenvironment during wound healing. LL-37 neutralizes lipopolysaccharide (LPS) and lipoteichoic acid (LTA) released by bacteria at wound sites, preventing excessive Toll-like receptor activation and the subsequent cytokine storm that can impair healing. Simultaneously, the peptide recruits mesenchymal stem cells to wound sites through FPR2-mediated chemotaxis, promoting regenerative repair processes. LL-37 also stimulates the release of anti-inflammatory cytokines including IL-10 while modulating the production of pro-inflammatory mediators.

Research into LL-37's role in biofilm disruption has garnered significant attention. Many chronic infections involve bacterial biofilms, structured communities of microorganisms encased in a protective extracellular matrix that confers resistance to conventional antibiotics. LL-37 has demonstrated the ability to penetrate and disrupt established biofilms through degradation of the extracellular polymeric substance (EPS) matrix and direct killing of biofilm-embedded bacteria. This anti-biofilm activity occurs at concentrations below those required for planktonic (free-floating) bacterial killing, suggesting a distinct mechanism of action against biofilm structures.

LL-37's interaction with the adaptive immune system adds another dimension to its immunological profile. The peptide enhances dendritic cell maturation and antigen presentation, promotes Th1 polarization of CD4+ T helper cells, and modulates B-cell function. These adaptive immune effects position LL-37 as a bridge molecule connecting rapid innate immune responses to sustained adaptive immunity.

Vitamin D regulation of LL-37 expression represents an important physiological connection. The CAMP gene promoter contains a vitamin D response element (VDRE) that is activated by the vitamin D receptor (VDR) upon binding of the active hormone 1,25-dihydroxyvitamin D3. This regulatory mechanism links vitamin D status directly to antimicrobial peptide production, providing a molecular explanation for the well-documented association between vitamin D deficiency and increased susceptibility to infections.

Preclinical and clinical research on LL-37 has been published in journals including the Journal of Immunology, Proceedings of the National Academy of Sciences, Antimicrobial Agents and Chemotherapy, and the Journal of Investigative Dermatology. Research continues to explore the peptide's therapeutic potential in wound healing, antimicrobial defense, biofilm-associated infections, and immune modulation.

## Mechanism of Action

### Step 1: Amphipathic Alpha-Helix Formation

LL-37 adopts an amphipathic alpha-helical structure in physiological conditions, with cationic residues on one face and hydrophobic residues on the other. This conformation enables electrostatic interaction with negatively charged microbial membranes.

### Step 2: Membrane Disruption & Antimicrobial Activity

LL-37 disrupts microbial membranes through carpet model accumulation and toroidal pore formation. The peptide also translocates intracellularly to interfere with DNA/RNA synthesis, protein folding, and cell wall biosynthesis, creating a multi-target antimicrobial mechanism.

### Step 3: FPR2 Receptor Activation

LL-37 activates formyl peptide receptor 2 (FPR2/ALX) on neutrophils, macrophages, and endothelial cells, triggering chemotaxis of immune cells to infection/injury sites and initiating wound healing signaling cascades.

### Step 4: EGFR Transactivation & Cell Migration

The peptide transactivates the epidermal growth factor receptor (EGFR) on keratinocytes, activating MAPK/ERK signaling to promote cell proliferation and migration essential for wound re-epithelialization and tissue repair.

### Step 5: Angiogenesis & Immune Modulation

LL-37 induces VEGF expression through HIF-1alpha stabilization, promoting new blood vessel formation. Simultaneously, it neutralizes bacterial endotoxins (LPS/LTA) to prevent excessive inflammation and recruits mesenchymal stem cells for regenerative repair.

## Researched Benefits

### Broad-Spectrum Antimicrobial Defense

LL-37 exhibits antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses through its multi-target membrane-disrupting mechanism. This broad-spectrum activity, combined with the inherent difficulty of developing resistance to membrane-disrupting peptides, makes LL-37 a valuable research tool for antimicrobial defense studies.

### Wound Healing Promotion

Through EGFR transactivation, FPR2-mediated cell recruitment, and VEGF-driven angiogenesis, LL-37 promotes all phases of wound repair. Its ability to simultaneously eliminate wound-colonizing microorganisms while stimulating tissue regeneration addresses both infectious and structural components of wound healing.

### Anti-Biofilm Activity

LL-37 penetrates and disrupts established bacterial biofilms at sub-bactericidal concentrations, degrading the protective extracellular matrix and killing biofilm-embedded organisms. This anti-biofilm activity is particularly relevant for chronic infections where conventional antibiotics demonstrate limited efficacy against biofilm-protected bacteria.

### Immunomodulatory Bridge Function

LL-37 bridges innate and adaptive immunity by enhancing dendritic cell maturation, promoting Th1 T-cell polarization, and modulating inflammatory cytokine profiles. This dual immunomodulatory role coordinates rapid antimicrobial responses with sustained adaptive immune surveillance.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 100-300mcg administered subcutaneously, protocol dependent on research context |
| Route | Subcutaneous injection |
| Duration | 2-6 weeks per cycle |
| Cycle Notes | Research protocols vary based on application. Antimicrobial-focused protocols may use shorter, more intensive courses, while wound healing protocols typically extend over 4-6 weeks. Rest periods between cycles are generally recommended to prevent receptor desensitization. |
| Reconstitution | Reconstitute with sterile water for injection or bacteriostatic water. LL-37 has a tendency to aggregate at high concentrations; reconstitute to recommended concentrations and use promptly. Store reconstituted solution at 2-8°C protected from light and use within 14 days. |

> **Specialist note:** A your specialist must evaluate immune status, active infections, concurrent antimicrobial therapies, and inflammatory conditions before initiating LL-37 protocols. The peptide's immunomodulatory properties require careful assessment in individuals with autoimmune conditions or those taking immunosuppressive medications.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >98% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser |
| Molecular Weight | 4493.3 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. Avoid repeated freeze-thaw cycles. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

LL-37 activates multiple immune pathways including inflammasome assembly, neutrophil chemotaxis, and dendritic cell maturation. Individuals with autoimmune conditions, chronic inflammatory disorders, or those taking immunosuppressive medications require thorough specialist assessment. The peptide's potent immunomodulatory activity can interact with concurrent antimicrobial and anti-inflammatory therapies, necessitating coordinated treatment planning.

## Frequently Asked Questions

### What is LL-37 and why is it significant in immunity research?

LL-37 is the only cathelicidin antimicrobial peptide produced by humans. Named for its two N-terminal leucine residues and 37-amino acid length, it is produced by neutrophils, macrophages, and epithelial cells as a key component of innate immune defense. Its significance lies in its dual functionality: direct antimicrobial activity against bacteria, fungi, and viruses, combined with potent immunomodulatory and wound healing properties.

### How does LL-37 kill microorganisms?

LL-37 uses multiple complementary mechanisms to eliminate microorganisms. Its amphipathic alpha-helical structure enables it to insert into negatively charged microbial membranes, forming pores and disrupting membrane integrity. The peptide can also translocate into microbial cells and interfere with DNA/RNA synthesis, protein folding, and cell wall biosynthesis. This multi-target approach makes it inherently difficult for microorganisms to develop resistance.

### What is the connection between vitamin D and LL-37?

The gene encoding LL-37 (CAMP) contains a vitamin D response element in its promoter. When the active form of vitamin D (1,25-dihydroxyvitamin D3) binds the vitamin D receptor, it activates CAMP gene transcription and increases LL-37 production. This molecular connection explains why vitamin D deficiency is associated with increased infection susceptibility and highlights the importance of adequate vitamin D status for antimicrobial peptide production.

### Can LL-37 address antibiotic-resistant infections?

LL-37's membrane-disrupting mechanism of action differs fundamentally from conventional antibiotics, and its multi-target approach makes resistance development inherently difficult. Research has also demonstrated LL-37's ability to disrupt bacterial biofilms, which are a major contributor to antibiotic treatment failure. These properties make LL-37 a subject of active research in the context of antimicrobial resistance.

### Is LL-37 safe for topical wound application?

Preclinical research has investigated topical LL-37 for wound healing applications with promising results in accelerating re-epithelialization and reducing wound infection. However, any clinical application of LL-37, whether topical or injectable, must be supervised by a qualified specialist. LL-37's potent immunomodulatory effects require careful dosing and monitoring to ensure therapeutic benefit without excessive inflammatory activation.

## Related Compounds

- /compounds/bpc-157
- /compounds/thymosin-beta-4
- /compounds/thymosin-alpha-1